Summary

The Stability of Atherosclerotic Plaque by Initiation of Darapladib Therapy trial [STABILITY; NCT00799903] showed that darapladib compared with placebo, did not significantly reduce the composite primary end point of cardiovascular death, myocardial infarction, and stroke in 15?828 patients with stable coronary heart disease on optimal medical therapy [White HD et al. N Engl J Med. 2014]. This article presents data from a predefined analysis of STABILITY designed to examine factors that contribute to high levels of Lp-PLA2 activity, whether its activity predicted outcomes or identified patients who would have a greater benefit with darapladib, and whether darapladib would provide persistent, long-term reduction of Lp-PLA2 activity.